Massimo Santoro
#151,001
Most Influential Person Now
Massimo Santoro's AcademicInfluence.com Rankings
Massimo Santorophilosophy Degrees
Philosophy
#8351
World Rank
#11710
Historical Rank
Logic
#5384
World Rank
#6778
Historical Rank

Massimo Santorobiology Degrees
Biology
#11288
World Rank
#14673
Historical Rank
Endocrinology
#166
World Rank
#178
Historical Rank
Molecular Biology
#1728
World Rank
#1757
Historical Rank

Download Badge
Philosophy Biology
Why Is Massimo Santoro Influential?
(Suggest an Edit or Addition)Massimo Santoro's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. (2015) (1442)
- BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. (2003) (1023)
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012) (985)
- PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas (1990) (954)
- Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B (1995) (838)
- Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer (2002) (749)
- ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) (611)
- BAY 43-9006 inhibition of oncogenic RET mutants. (2006) (480)
- MicroRNA deregulation in human thyroid papillary carcinomas. (2006) (418)
- A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases (1987) (403)
- Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. (2007) (395)
- Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. (1992) (391)
- Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. (1994) (376)
- Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2007) (363)
- Mutation of the PIK3CA gene in anaplastic thyroid cancer. (2005) (336)
- RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. (1998) (329)
- The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2005) (322)
- High level expression of the HMGI (Y) gene during embryonic development. (1996) (315)
- The RET receptor: function in development and dysfunction in congenital malformation. (2001) (288)
- High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. (1989) (282)
- Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. (2004) (278)
- RET/PTC oncogene activation is an early event in thyroid carcinogenesis. (1995) (270)
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. (2013) (261)
- The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. (1998) (260)
- Expression of the RET/PTC Fusion Gene as a Marker for Papillary Carcinoma in Hashimoto's Thyroiditis (1997) (255)
- High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. (1999) (255)
- Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* (2006) (251)
- Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. (1996) (249)
- The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. (1990) (246)
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors (2004) (238)
- Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. (1992) (235)
- Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. (1994) (232)
- The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. (1999) (213)
- Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2002) (211)
- Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells (1995) (210)
- RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. (2006) (198)
- The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. (1995) (198)
- Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression (1997) (197)
- BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. (2004) (194)
- RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. (2006) (187)
- New therapeutic approaches to treat medullary thyroid carcinoma (2008) (184)
- Mast cells have a protumorigenic role in human thyroid cancer (2010) (184)
- BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma (2006) (182)
- Targeting the RET Pathway in Thyroid Cancer (2009) (181)
- Minireview: RET: normal and abnormal functions. (2004) (176)
- Molecular Mechanisms of RET Activation in Human Cancer (2002) (169)
- A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. (2007) (166)
- Neoplastic transformation of rat thyroid cells requires the junB and fra‐1 gene induction which is dependent on the HMGI‐C gene product (1997) (163)
- Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. (1996) (160)
- Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway (2015) (159)
- Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. (2004) (155)
- Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. (1998) (154)
- PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 (2000) (153)
- RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid (2000) (148)
- The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. (2002) (146)
- Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade (2001) (145)
- Molecular heterogeneity of RET loss of function in Hirschsprung's disease. (1996) (145)
- Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. (2002) (144)
- The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. (1993) (143)
- Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret (1998) (139)
- Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. (2004) (139)
- Inhibitory Effects of Peroxisome Proliferator-Activated Receptor γ on Thyroid Carcinoma Cell Growth (2002) (139)
- NCOA4 Deficiency Impairs Systemic Iron Homeostasis. (2016) (136)
- Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas (2004) (134)
- Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers (1994) (132)
- Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts (1998) (132)
- Developmental expression of the RET protooncogene. (1994) (131)
- Gene rearrangement and Chernobyl related thyroid cancers (2000) (126)
- An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway (1994) (125)
- A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts (2011) (123)
- Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). (2003) (121)
- Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1 (2000) (120)
- RET activation and clinicopathologic features in poorly differentiated thyroid tumors. (2002) (115)
- UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas (2005) (114)
- Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines (1998) (114)
- The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium (2000) (112)
- The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. (2007) (111)
- The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. (2007) (111)
- Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (2002) (111)
- The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. (2002) (106)
- Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. (2009) (103)
- Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway (2001) (103)
- Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung Cancer (2005) (102)
- The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. (1997) (102)
- Transplantation of Germ Cells from Glial Cell Line-Derived Neurotrophic Factor-Overexpressing Mice to Host Testes Depleted of Endogenous Spermatogenesis by Fractionated Irradiation1 (2002) (101)
- Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation (2001) (95)
- Dysfunction of the RET receptor in human cancer. (2004) (94)
- High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth (2001) (93)
- Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia. (2000) (93)
- Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. (2000) (92)
- A Novel Member of the BTB/POZ Family, PATZ, Associates with the RNF4 RING Finger Protein and Acts as a Transcriptional Repressor* (2000) (92)
- Central role of RET in thyroid cancer. (2013) (92)
- Thyroid cell transformation requires the expression of the HMGA1 proteins (2002) (92)
- Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. (2007) (86)
- The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway (2002) (85)
- The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. (2009) (84)
- Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. (2005) (83)
- The ret/ptc1 oncogene is activated in familial adenomatous polyposis-associated thyroid papillary carcinomas. (1998) (83)
- Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. (2013) (82)
- Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. (2005) (82)
- Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. (2001) (77)
- Drug Insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer (2006) (77)
- Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells (2010) (77)
- Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. (2007) (76)
- The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret (2001) (76)
- The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. (2010) (76)
- Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. (1993) (75)
- RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. (2002) (75)
- Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. (1995) (74)
- Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. (1992) (74)
- Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. (2003) (74)
- Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. (2009) (74)
- Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants (2007) (73)
- Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors (2003) (72)
- Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? (1999) (72)
- Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). (2010) (70)
- Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas (2006) (70)
- Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. (2008) (69)
- HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. (2008) (68)
- Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line (1995) (68)
- Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. (2014) (67)
- Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer (2005) (66)
- Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. (1999) (66)
- XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway (2009) (65)
- CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model (2013) (64)
- siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (64)
- Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells (2003) (64)
- Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo (1998) (64)
- An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. (2003) (64)
- Cloning and characterization of H4 (D10S170), a gene involved in RET rearrangements in vivo. (1994) (63)
- The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). (1989) (63)
- CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. (2012) (62)
- Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. (2009) (62)
- Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. (1998) (62)
- Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. (2001) (62)
- Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. (1997) (62)
- The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane (2001) (61)
- High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases (2001) (61)
- Dysregulated RET signaling in thyroid cancer. (2008) (59)
- RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. (2007) (59)
- Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. (1996) (58)
- Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. (2000) (58)
- Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. (1995) (58)
- Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells (2010) (57)
- RET Gene Fusions in Malignancies of the Thyroid and Other Tissues (2020) (56)
- RNF4 is a growth inhibitor expressed in germ cells but not in human testicular tumors. (2001) (56)
- The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. (2002) (55)
- Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (2016) (55)
- Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness (2005) (54)
- Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment. (1997) (54)
- Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells (2004) (54)
- Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. (2002) (53)
- Ret-mediated mitogenesis requires Src kinase activity. (1999) (53)
- FRA-1 expression in hyperplastic and neoplastic thyroid diseases. (2000) (53)
- Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes (2003) (52)
- Thymosin β-10 Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro (1998) (52)
- Simian virus 40-like DNA sequences in human papillary thyroid carcinomas (1998) (51)
- RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association. (2014) (51)
- The Adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. (1993) (50)
- Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. (2011) (50)
- Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation. (1992) (50)
- Extracellular superoxide dismutase is a growth regulatory mediator of tissue injury recovery. (2009) (49)
- Cooperation between the polyomavirus middle-T-antigen gene and the human c-myc oncogene in a rat thyroid epithelial differentiated cell line: model of in vitro progression (1988) (49)
- A mutated p53 gene alters thyroid cell differentiation. (1995) (49)
- Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells (2004) (49)
- NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. (2014) (48)
- Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation* (2013) (47)
- Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement (2002) (46)
- Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas (2001) (46)
- Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours. (1996) (46)
- Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? (1999) (46)
- The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. (2006) (45)
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. (2018) (45)
- Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. (2005) (44)
- The importance of the RET gene in thyroid cancer and therapeutic implications (2021) (44)
- The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. (2004) (44)
- RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho (2001) (44)
- TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. (2011) (42)
- Overexpression of proteins HMGA1 induces cell cycle deregulation and apoptosis in normal rat thyroid cells. (2018) (42)
- Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene* (2006) (42)
- A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. (1996) (42)
- Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis. (2013) (42)
- XB130 Mediates Cancer Cell Proliferation and Survival through Multiple Signaling Events Downstream of Akt (2012) (41)
- Receptor tyrosine kinase inhibitors in thyroid cancer. (2008) (40)
- CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas (2012) (40)
- Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. (1991) (39)
- Molecular mechanisms of RET activation in human neoplasia (1999) (39)
- Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. (1998) (39)
- Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. (2008) (39)
- OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome (2007) (39)
- Oncogenes and Thyroid Cancer (2000) (39)
- 20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. (2007) (38)
- A new mechanism of BRAF activation in human thyroid papillary carcinomas. (2005) (38)
- Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. (2018) (37)
- RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors (2005) (37)
- A novel de novo germ‐line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization (2009) (37)
- FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. (2012) (36)
- Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. (1999) (36)
- Protein kinase Cα activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase (2003) (36)
- The Kirsten murine sarcoma virus induces rat thyroid carcinomas in vivo. (1989) (35)
- A novel pathway of cell growth regulation mediated by a PLA2α‐derived phosphoinositide metabolite (2006) (35)
- CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 (2010) (35)
- Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. (2011) (35)
- Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. (2000) (35)
- SOD3 Decreases Ischemic Injury Derived Apoptosis through Phosphorylation of Erk1/2, Akt, and FoxO3a (2011) (35)
- Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. (2008) (34)
- Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. (2015) (34)
- Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. (1995) (33)
- A truncated HMGA1 gene induces proliferation of the 3T3-L1 pre-adipocytic cells: a model of human lipomas. (2003) (33)
- Identification and characterization of a novel RING-finger gene (RNF4) mapping at 4p16.3. (1998) (32)
- Rat protein tyrosine phosphatase η physically interacts with the PDZ domains of syntenin (2001) (32)
- Identification of RET Kinase Inhibitors as Potential New Treatment for Sporadic and Inherited Thyroid Cancer (2004) (30)
- Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. (2010) (30)
- A TSH-CREB1-microRNA loop is required for thyroid cell growth. (2011) (30)
- High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. (2001) (30)
- Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma (2014) (29)
- Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. (1996) (29)
- Loss of p27 Expression Through RAS->BRAF->MAP Kinase-Dependent Pathway in Human Thyroid Carcinomas (2007) (29)
- HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. (2003) (29)
- Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis. (2003) (29)
- Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. (1995) (28)
- Update: the status of clinical trials with kinase inhibitors in thyroid cancer. (2014) (28)
- A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma. (2008) (28)
- Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. (1998) (27)
- CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. (2010) (27)
- Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. (2009) (26)
- Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies (2014) (26)
- Cloning of the rat tissue inhibitor of metalloproteinases type 2 (TIMP-2) gene: analysis of its expression in normal and transformed thyroid cells. (1994) (25)
- Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells (2014) (25)
- Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas (2005) (25)
- Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas. (1998) (24)
- Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin (2004) (24)
- The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC. (2010) (24)
- RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block. (2010) (23)
- The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (23)
- Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases (2012) (23)
- In Vivo and in Vitro Characterization of a Novel Germline RET Mutation Associated with Low-Penetrant Nonaggressive Familial Medullary Thyroid Carcinoma (2006) (22)
- Presence of physiologically stimulated RET in adult rat brain: induction of RET expression during nerve regeneration. (1996) (22)
- The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. (2017) (22)
- Morphological ultrasound microimaging of thyroid in living mice. (2009) (22)
- The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. (2016) (21)
- Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. (2012) (21)
- Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. (2008) (21)
- Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1 (2002) (19)
- Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase (2015) (19)
- Molecular Cloning of PTC, a New Oncogene Found Activated in Human Thyroid Papillary Carcinomas and Their Lymph Node Metastases a (1988) (19)
- Molecular biomarkers in thyroid FNA samples. (2012) (18)
- Erratum: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells (American Society for Clinical Investigation (2005) 115:4 (1068-1081) DOI: 10.1172/JCI22758) (2016) (18)
- Receptor tyrosine kinases as targets for anticancer therapeutics. (2005) (18)
- Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis. (2000) (17)
- Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. (2014) (16)
- Different mutations of the RET gene cause different human tumoral diseases. (1999) (16)
- Protein tyrosine phosphatase-eta expression is upregulated by the PKA-dependent and is downregulated by the PKC-dependent pathways in thyroid cells. (1998) (16)
- The high transforming potency of erbB-2 and ret is associated with phosphorylation of paxillin and a 23 kDa protein. (1994) (16)
- Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. (2009) (16)
- A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma (2017) (16)
- Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology (2020) (15)
- Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase. (2002) (15)
- Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1* (2016) (15)
- Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B* (1996) (15)
- Thyroid cancer in 2010: A roadmap for targeted therapies (2011) (15)
- Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential. (1997) (15)
- Is Co-option a prevailing mechanism during cancer progression? (2011) (15)
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2018) (14)
- Cytosolic Phospholipase A2α Regulates Cell Growth in RET/PTC-Transformed Thyroid Cells (2007) (14)
- A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability (2016) (13)
- The Kinase Inhibitor PP 1 Blocks Tumorigenesis Induced by RET Oncogenes 1 (2002) (13)
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. (2021) (13)
- The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive. (2000) (12)
- Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready? (2010) (12)
- Genetics: The genomic landscape of papillary thyroid carcinoma (2015) (12)
- Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. (2006) (12)
- Pivotal role of the RB family proteins in in vitro thyroid cell transformation. (2000) (11)
- The rat tyrosine phosphatase η increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue (2005) (11)
- Activated RET oncogene products induce maturation of xenopus oocytes. (1995) (10)
- Oncogenic rearrangements driving ionizing radiation-associated human cancer. (2013) (10)
- Regulation of thymosin beta10 expression by TSH and other mitogenic signals in the thyroid gland and in cultured thyrocytes. (1999) (10)
- Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). (2002) (9)
- Medullary thyroid carcinomas in transgenic mice expressing a Polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens (1999) (9)
- The ret protooncogene is expressed in normal human parafollicular thyroid-cells. (1994) (9)
- Regulation of p 27 Kip 1 Protein Levels Contributes to Mitogenic Effects of the RET / PTC Kinase in Thyroid Carcinoma Cells (2004) (8)
- Oncogenic protein tyrosine kinases (2004) (7)
- Receptor- and Non-Receptor Tyrosine Kinases Induce Processing of the Amyloid Precursor Protein: Role of the Low-Density Lipoprotein Receptor-Related Protein (2007) (7)
- Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia (2018) (7)
- TPA induces a block of differentiation and increases the susceptibility to neoplastic transformation of a rat thyroid epithelial cell line. (1998) (7)
- The tyrosine kinase inhibitor ZD 6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells (2010) (7)
- New drugs in thyroid cancer. (2007) (7)
- Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells. (2007) (6)
- CaV 2 . 3 channel and PKC λ : new players in insulin secretion (2004) (6)
- Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms. (2019) (6)
- Thyroid cancer: A molecular perspective (2010) (5)
- Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice. (2001) (5)
- Overexpression of Proteins HMGA 1 Induces Cell Cycle Deregulation and Apoptosis in Normal Rat Thyroid Cells 1 (2001) (5)
- EXTENSIVE CLINICAL EXPERIENCE Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma (2007) (5)
- Impairment of the p 27 kip 1 function enhances thyroid carcinogenesis in TRK-T 1 transgenic mice (2009) (5)
- CD 44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells (2012) (5)
- siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma (2007) (4)
- Norepinephrine and thyrotropin stimulation of [Ca++]i in PC C13 a rat thyroid epithelial cell line: effect of transformation by E1A gene adenovirus and polyomavirus middle-T antigen gene. (1993) (4)
- NCOA4 links iron bioavailability to DNA metabolism. (2022) (4)
- Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases (2021) (4)
- Ret-mediated Mitogenesis Requires Src Kinase Activity 1 (1999) (3)
- Structure and Chemical Inhibition of the RET Tyrosine (2006) (3)
- Circulating long non-coding RNA signature in knee osteoarthritis patients with postoperative pain one-year after total knee replacement (2021) (3)
- Association between the expression of E1A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells. (2000) (3)
- Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. (2005) (2)
- RFLP for TaqI of the human thyroid papillary carcinoma (PTC) oncogene. (1988) (2)
- Association between the expression of E 1 A oncogene and increased sensitivity to growth inhibition induced by sustained levels of cAMP in rat thyroid cells (2000) (2)
- Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. (2009) (2)
- Pros and cons of cellular studies in developing new drugs for thyroid cancers. (2008) (2)
- Retraction for Berlingieri et al., “Inhibition of HMGI-C Protein Synthesis Suppresses Retrovirally Induced Neoplastic Transformation of Rat Thyroid Cells” (2018) (1)
- Endocannabinoids as emerging suppressors of angiogenesis and breast tumor growth and metastatic spreading ” (2008) (1)
- Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells (2014) (1)
- The ret protooncogene is expressed in predominantly epithelial human thymomas. (1994) (1)
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. (2022) (1)
- Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ” (2008) (1)
- thyroid carcinogenesis in TRK-T1 transgenic mice (2009) (1)
- 1505: Ultrasound Micro-Imaging of Thyroid in Living Mice (2009) (1)
- Pathogenesis of Thyroid Carcinoma (2016) (1)
- Attacking cancer with molecularly targeted agents. (2013) (1)
- Genetic alterations in differentiated thyroid cancer: what can be expected for gene expression profiling of thyroid carcinomas. (2003) (1)
- Thyroid Neoplastic Transformation In Vitro and In Vivo (1984) (1)
- Identification of a Chimeric Gene Frequently Activated in Human Thyroid Papillary Carcinomas (1993) (1)
- Intracellular Signaling by the ret Tyrosine Kinase (1996) (1)
- The PTC oncogene is able to dedifferentiate a rat thyroid epithelial cell line in culture (1992) (1)
- The RET Receptor Family (2015) (1)
- SymposiumRole of oncogene activation in human thyroid carcinomas (1990) (1)
- Control of breast cancer cell growth by adipocyte-released factors ” (2009) (1)
- Activation of the ret oncogene in human thyroid carcinomas (1993) (1)
- RET: A Multi-Faceted Gene in Human Cancer (2012) (1)
- Inside Back Cover: Fragment‐Based Discovery of a Dual pan‐RET/VEGFR2 Kinase Inhibitor Optimized for Single‐Agent Polypharmacology (Angew. Chem. Int. Ed. 30/2015) (2015) (0)
- Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity (1997) (0)
- statementregardingthepossibilityofsuchanadverseeventisincluded onthevandetaniblabel,andthereisarequirementthateachphysician who prescribes vandetanib (in the United States) complete an educa- tional program that addresses the risks of QTc prolongation. (2012) (0)
- Retraction: Suppression of HMGA2 Protein Synthesis Could Be a Tool for the Therapy of Well Differentiated Liposarcomas Overexpressing HMGA2. (2018) (0)
- Patologia. - Glial cell line-derived neurotrophic factor (GDNF) stimulates ret activity (1997) (0)
- Role of the calcium-calmodulin dependent kinase 2 in medullary thyroid carcinoma (2013) (0)
- Medullary Thyroid Cancer Cells inCalcitonin Gene Expression through Distinct Mechanisms The RET Kinase Inhibitor NVP-AST 487 Blocks Growth and Updated (2007) (0)
- Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. (2018) (0)
- Malignant Phenotype in Thyroid Cancer Gene Expression Correlates with a Highly CBX 7 Loss of the Updated (2008) (0)
- Human Cancer Biology Activationof themTORPathway inPrimaryMedullary Thyroid Carcinoma and Lymph Node Metastases (2012) (0)
- New findings in growth factor receptors and integrins cross-talk (2003) (0)
- Signaling Pathway to the Phosphatidylinositol 3-Kinase / Akt Protein Inhibits Apoptosis by Coupling Ret ) Adaptor ShcC ( Rai The Neuron-Specific (2002) (0)
- Retraction for Trapasso et al., “Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1” (2018) (0)
- Thymosin ß-10Gene Overexpression Correlated with the Highly Malignant Neoplastic Phenotype of Transformed Thyroid Cells in Vivo and in Vitro1 (2006) (0)
- Molecular and genetic alterations in human thyroid carcinomas (1997) (0)
- Molecular mechanisms in thyroid cancer (2010) (0)
- Effect of viral oncogenes transformation on TSH- and norepinephrine-evoked [Ca++]i increase in rat thyroid cells (1992) (0)
- RON IS A HETERODIMERIC TYROSINE KINASE RECEPTOR ACTIVATED BY THE HGF HOMOLOG MSP / G. GAUDINO; A. FOLLENZI; L. NALDINI; C. COLLESI; M. SANTORO; (0)
- Correction to: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2022) (0)
- The role of autophagy in neoplastic cell response to oncolytic viruses ” (2009) (0)
- Doctorate Program in Molecular Oncology and Endocrinology (2006) (0)
- Osteopontin Expression Predicts the Clinical Outcome of Laryngeal Intraepithelial Neoplasia (2007) (0)
- RET Recognition of GDNF-G FR a 1 Ligand by a Composite Binding Site Promotes Membrane-Proximal Self-Association Graphical (2014) (0)
- Patologia. -- Glial Ceil Line-Derzved Neurotrophic Factor (GDNF) stimulates Ret activity. Nota di FRANCESCA CARLOMAGNO, ROSA MARINA MELILLO, GIULIANA SALVATORE, (1997) (0)
- New genes involved in the neoplastic transformation of the thyroid gland (2006) (0)
- ActivationofthemTORPathwayinPrimaryMedullaryThyroid Carcinoma and Lymph Node Metastases (2012) (0)
- RECEPTOR TYROSINE KINASES AS TARGET FOR ANTI-CANCER THERAPY RECEPTOR TYROSINE KINASES AS TARGET FOR ANTI-CANCER THERAPY (0)
- Downregulation of Alpha‐L‐Fucosidase Expression Is Related to Dedifferentiation and Worse Prognosis in Thyroid and Breast Cancer. (2016) (0)
- Gene expression profile analysis of pituitary adenomas developed by HMGA transgenic mice ” (2007) (0)
- Detection ofRET oncogeneactivation inhumanpapillary thyroid carcinomas byinsitu hybridisation (1992) (0)
- Gefitinib and Radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck ” (2008) (0)
- Molecular and Cellular Pathobiology CD 44 Proteolysis Increases CREB Phosphorylation and Sustains Proliferation of Thyroid Cancer Cells (2012) (0)
- a Potential Diagnostic Indicator of Carcinoma Diagnosis of Thyroid Tumors : HMGI ( Y ) Expression Represents Detection of High Mobility Group I HMGI ( Y ) Protein in the Updated Version (2006) (0)
- New biomolecular prognostic and predictive factors of response to treatments in colorectal cancer ” (2010) (0)
- Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. (2020) (0)
- Sulfate-binding Protein in Human Thyroid Carcinomas Gene Coding for a Heparin / Heparan HIP Overexpression of the Updated (2006) (0)
- Calcium-calmodulin dependent kinase II is activated by mutated RET in medullary thyroid carcinoma (2010) (0)
- Pathogenesis of Thyroid Cancer (2021) (0)
- Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases (2019) (0)
- The Cooperation between Viral ras Genes and Different Immortalizing Genes Induces the Transformation of Rat Thyroid Epithelial Cells (1989) (0)
- Molecular pathogenesis of MTC: Role of RET oncogene (2012) (0)
- 45th Annual Meeting of the Italian Cancer Society Bergamo, 9-12 November 2003 (2004) (0)
- PTC in thyroid tumours (1993) (0)
- Molecular mechanisms of insulin resistance : role of endocannabinoid system in the regulation of glucose metabolism and insulin action ” (2007) (0)
- Ribonucleases as antitumor agents (2003) (0)
- Absence of Dedifferentiating and Transforming Effects Hormone-independent Proliferation of Thyroid Cells in the Akt / Protein Kinase B Promotes Survival and Updated (2000) (0)
- Roles of mast cells and their mediators in human thyroid carcinomas (2007) (0)
- A novel pathway of cell growth regulation mediated by a PLA 2 (cid:1) -derived phosphoinositide metabolite (2006) (0)
- Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab (2012) (0)
- Developmental Expression of the RET Protooncogene 1 (2005) (0)
- Innenrücktitelbild: Fragment‐Based Discovery of a Dual pan‐RET/VEGFR2 Kinase Inhibitor Optimized for Single‐Agent Polypharmacology (Angew. Chem. 30/2015) (2015) (0)
- PTC oncogenic signaling through the Rap 1 small GTPase (2013) (0)
- Retraction for Melillo et al., “Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation” (2018) (0)
- Reply to J.-F. Chatal et al (2012) (0)
- Molecular Pathways Targeting the RET Pathway in Thyroid Cancer (2009) (0)
- Indoleamine 2,3-dioxygenase 1 (IDO1) and thyroid carcinoma: Ret/PTC appears as a strong genetic determinant for IDO1 expression (2012) (0)
- ergistic Antitumor Activity of Sorafenib in Combination Epidermal Growth Factor Receptor Inhibitors in R orectal and Lung Cancer Cells (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Massimo Santoro?
Massimo Santoro is affiliated with the following schools: